<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03088410</url>
  </required_header>
  <id_info>
    <org_study_id>IRB 2019-2922</org_study_id>
    <secondary_id>R01DK109881</secondary_id>
    <secondary_id>HRDC 00781</secondary_id>
    <nct_id>NCT03088410</nct_id>
  </id_info>
  <brief_title>Study of HIV-Infected and Uninfected Pregnant Woman/Child Dyads in Gaborone, Botswana</brief_title>
  <official_title>The Tshilo Dikotla Study: Metabolic Outcomes of Children HIV/ARV-Exposed Uninfected in Botswana (MOCHA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ann &amp; Robert H Lurie Children's Hospital of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Ann &amp; Robert H Lurie Children's Hospital of Chicago</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the early longitudinal metabolic effects including&#xD;
      insulin sensitivity in HIV-exposed uninfected (HEU) children compared to HIV-unexposed&#xD;
      uninfected (HUU) children; as well as to determine differences in the effects of neonatal&#xD;
      zidovudine (AZT) vs. nevirapine (NVP) prophylaxis on early longitudinal changes in insulin&#xD;
      sensitivity in the first 3 years of life.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will consist of a nested randomized component of HIV-infected (HIV+) and&#xD;
      -uninfected (HIV-) pregnant woman/child dyads in Botswana which will take place in Gaborone,&#xD;
      Botswana at Botswana-Harvard AIDS Institute Partnership's (BHPs) clinical research&#xD;
      facilities. A total of 300 HIV+ pregnant woman/fetus dyads on cART and 150 HIV- pregnant&#xD;
      woman/fetus dyads will be evaluated for insulin sensitivity and followed through the child's&#xD;
      3rd birthday. Amongst HEU infants, participants will be randomized at birth 1:1 with 150 to&#xD;
      receive neonatal AZT prophylaxis and 150 to receive neonatal NVP prophylaxis. Targeted&#xD;
      metabolomics will be used to assess the role intermediary metabolites in insulin resistance&#xD;
      and directly assess mitochondrial function using Seahorse XF96e technology. At the time of&#xD;
      study enrollment, all women must be willing to exclusively breastfeed for the infant's first&#xD;
      6 months of life. If in utero and neonatal HIV/ARV exposures are found to be associated with&#xD;
      derangements in intermediary metabolism such that HEU infants are at increased risk for&#xD;
      insulin resistance by 3 years of age, this would impact screening and prevention strategies&#xD;
      for diabetes in this vulnerable population and argue for further research to identify&#xD;
      prenatal and neonatal ARV regimens with superior PMTCT efficacy but minimal adverse metabolic&#xD;
      consequences.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 22, 2016</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Single blind - one party, either the investigator or participant, is unaware of the intervention assignment.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Homeo-static Model Assessment-Insulin Resistance (HOMA-IR)</measure>
    <time_frame>up to 3 years</time_frame>
    <description>[glucose (mg/dL) X insulin ( μU/mL)405]</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">495</enrollment>
  <condition>HIV</condition>
  <condition>Insulin Sensitivity</condition>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Nevirapine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>150 HIV-Exposed Uninfected (HEU) infants on Nevirapine (NVP) Prophylaxis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Zidovudine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>150 HIV-Exposed Uninfected (HEU) infants on Zidovudine (AZT) Prophylaxis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HIV- unexposed Uninfected (HUU) Infants</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>150 HIV- unexposed Uninfected (HUU) Infants</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine</intervention_name>
    <description>neonatal 4 weeks prophylactic</description>
    <arm_group_label>Zidovudine</arm_group_label>
    <other_name>AZT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nevirapine</intervention_name>
    <description>neonatal 4 weeks prophylactic</description>
    <arm_group_label>Nevirapine</arm_group_label>
    <other_name>NVP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  HIV-infected and uninfected pregnant women between 16-36 weeks GA are eligible for&#xD;
             study enrollment.&#xD;
&#xD;
          -  Women must be 18 years of older and able to provide informed consent for themselves&#xD;
             and their infant to participate in the study.&#xD;
&#xD;
          -  Participants must be Botswana citizens.&#xD;
&#xD;
          -  Women must have evidence of HIV infection status. Women NOT documented as HIV&#xD;
             seropositive must have documentation of HIV seronegativity during the present&#xD;
             pregnancy at or after 32 weeks GA. Women who have an initial negative HIV test during&#xD;
             the present pregnancy which was done at &lt;32 weeks GA will need to undergo repeat&#xD;
             testing on or after 32 weeks GA in accordance with national guidelines.&#xD;
&#xD;
          -  HIV-uninfected women must be willing to undergo HIV pre-test counseling, rapid HIV&#xD;
             testing and post-test counseling, referred to as HIV Testing and Counseling (HTC)&#xD;
             during pregnancy.&#xD;
&#xD;
          -  Women must be willing to remain in study area with their infant and attend scheduled&#xD;
             study visits as described above until the child's 3rd birthday.&#xD;
&#xD;
          -  For HIV-infected women, they must be on TDF/3TC or FTC/EFV or TDF/3TC or&#xD;
             FTC/Dolutegravir at time of study enrollment or willing to initiate this treatment and&#xD;
             continue throughout the period of breastfeeding, if not for their lifetime.&#xD;
&#xD;
          -  At enrollment, all women must be willing to breastfeed exclusively for the first six&#xD;
             months of life.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        •Pre-existing maternal diabetes mellitus.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer Jao, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ann &amp; Robert H Lurie Children's Hospital of Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Botswana-Harvard AIDS Institute Partnership</name>
      <address>
        <city>Gaborone</city>
        <country>Botswana</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Botswana</country>
  </location_countries>
  <reference>
    <citation>Banda FM, Powis KM, Sun S, Makhema J, Masasa G, Yee LM, Jao J. Fetal biometry following in-utero exposure to dolutegravir-based or efavirenz-based antiretroviral therapy. AIDS. 2020 Dec 1;34(15):2336-2337. doi: 10.1097/QAD.0000000000002674.</citation>
    <PMID>32910067</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 3, 2017</study_first_submitted>
  <study_first_submitted_qc>March 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2017</study_first_posted>
  <last_update_submitted>March 8, 2021</last_update_submitted>
  <last_update_submitted_qc>March 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ann &amp; Robert H Lurie Children's Hospital of Chicago</investigator_affiliation>
    <investigator_full_name>Jennifer Jao</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Nevirapine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

